Penumbra, Inc. (NYSE:PEN – Get Free Report) Director Harpreet Grewal sold 782 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $204.11, for a total transaction of $159,614.02. Following the sale, the director now directly owns 8,863 shares in the company, valued at $1,809,026.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Penumbra Stock Performance
NYSE PEN opened at $203.73 on Friday. Penumbra, Inc. has a fifty-two week low of $148.00 and a fifty-two week high of $302.00. The firm has a market capitalization of $7.90 billion, a P/E ratio of 85.96, a price-to-earnings-growth ratio of 2.26 and a beta of 0.54. The stock’s fifty day moving average is $187.35 and its two-hundred day moving average is $202.33. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.77 and a current ratio of 6.25.
Penumbra (NYSE:PEN – Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.08. The firm had revenue of $299.40 million during the quarter, compared to analyst estimates of $298.24 million. Penumbra had a net margin of 1.26% and a return on equity of 8.39%. Penumbra’s quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.43 earnings per share. On average, research analysts anticipate that Penumbra, Inc. will post 2.64 earnings per share for the current year.
Analysts Set New Price Targets
Check Out Our Latest Report on Penumbra
Institutional Trading of Penumbra
Several institutional investors have recently made changes to their positions in PEN. Benjamin F. Edwards & Company Inc. grew its position in Penumbra by 171.8% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 106 shares of the company’s stock worth $27,000 after acquiring an additional 67 shares during the period. Mather Group LLC. acquired a new position in shares of Penumbra in the 1st quarter valued at $29,000. WASHINGTON TRUST Co purchased a new position in shares of Penumbra during the 2nd quarter worth $54,000. Northwestern Mutual Wealth Management Co. increased its position in shares of Penumbra by 1,845.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 389 shares of the company’s stock worth $70,000 after purchasing an additional 369 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of Penumbra during the 4th quarter worth about $71,000. Hedge funds and other institutional investors own 88.88% of the company’s stock.
About Penumbra
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Featured Stories
- Five stocks we like better than Penumbra
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Canadian Penny Stocks: Can They Make You Rich?
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- Buy P&G Now, Before It Sets A New All-Time High
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.